In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 251 to 275 of 441

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]	Technology appraisal guidance	TBC
Nemolizumab for treating prurigo nodularis [ID6451]	Technology appraisal guidance	TBC
Neonatal infection: antibiotics for prevention and treatment - update	NICE guideline	13 May 2026
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446	Technology appraisal guidance	25 September 2026
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]	Technology appraisal guidance	TBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]	Technology appraisal guidance	28 June 2017
Nipocalimab for treating generalised myasthenia gravis [ID6562]	Technology appraisal guidance	TBC
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]	Technology appraisal guidance	TBC
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]	Technology appraisal guidance	TBC
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]	Technology appraisal guidance	TBC
Nirogacestat for treating desmoid tumours [ID6453]	Technology appraisal guidance	TBC
Nitazoxanide for treating the common cold in people 12 years and over [ID4049]	Technology appraisal guidance	TBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]	Technology appraisal guidance	28 January 2026
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]	Technology appraisal guidance	17 July 2024
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]	Technology appraisal guidance	TBC
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]	Technology appraisal guidance	TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]	Technology appraisal guidance	29 July 2026
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]	Technology appraisal guidance	TBC
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]	Technology appraisal guidance	TBC
Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]	Technology appraisal guidance	4 November 2026
Non-invasive skin closure devices for surgical incisions (MT775)	Medical technologies guidance	TBC
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]	Technology appraisal guidance	TBC
NY-ESO-1 T-cells for treating synovial sarcoma ID1286	Technology appraisal guidance	TBC

Results per page

10
25
50
All